Loading…
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.8B | $220M | $-1.1B | $-303M | 238.8% | 3.1% | - |
| 2024 | $2.7B | $-41M | $-363M | $-21M | -61.9% | 5.0% | - |
| 2023 | $2.6B | $342M | $-41M | $562M | -4.5% | -74.4% | -284.5% |
| 2022 | $10.0B | $368M | $22M | $158M | 2.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 9,955.48 | 2,552.57 | 2,680.11 | 2,762.03 |
| Cost Of Revenue | 8,129.12 | 1,335.55 | 1,399.73 | 1,472.73 |
| Gross Profit | 1,826.35 | 1,217.02 | 1,280.38 | 1,289.30 |
| Operating Expense | 1,549.57 | 1,001.66 | 1,082.34 | 1,067.56 |
| Operating Income | 276.78 | 215.36 | 198.04 | 221.74 |
| EBITDA | 368.45 | 342.40 | -41.04 | 219.75 |
| EBIT | 139.78 | 132.03 | -222.32 | 5.23 |
| Pretax Income | 10.89 | 15.27 | -329.88 | -101.95 |
| Tax Provision | -11.50 | 6.36 | 20.85 | 0.73 |
| Net Income | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income Common Stockholders | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Total Expenses | 9,678.69 | 2,337.21 | 2,482.08 | 2,540.29 |
| Interest Expense | 128.89 | 116.77 | 107.57 | 107.18 |
| Selling General And Administration | 1,554.82 | 1,001.66 | 1,082.34 | 1,067.56 |
| Normalized EBITDA | 502.32 | 424.54 | 374.73 | 432.32 |
| Normalized Income | 128.15 | 73.79 | -22.28 | 65.25 |
| Basic EPS | 0.30 | -0.54 | -4.73 | 0 |
| Diluted EPS | 0.29 | -0.54 | -4.73 | 0 |
| Tax Effect Of Unusual Items | -28.11 | -17.25 | -87.31 | -44.64 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -133.87 | -82.13 | -415.77 | -212.57 |
| Total Unusual Items Excluding Goodwill | -133.87 | -82.13 | -415.77 | -212.57 |
| Net Income From Continuing Operation Net Minority Interest | 22.39 | 8.90 | -350.74 | -102.68 |
| Reconciled Depreciation | 228.67 | 210.37 | 181.28 | 214.52 |
| Reconciled Cost Of Revenue | 8,129.12 | 1,335.55 | 1,399.73 | 1,472.73 |
| Net Interest Income | -128.89 | -116.77 | -107.57 | -107.18 |
| Net Income From Continuing And Discontinued Operation | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Total Operating Income As Reported | 142.91 | 133.23 | -217.73 | 27.46 |
| Diluted Average Shares | 76.22 | 75.78 | 76.74 | 0 |
| Basic Average Shares | 74.50 | 75.78 | 76.74 | 0 |
| Diluted NI Availto Com Stockholders | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income Including Noncontrolling Interests | 22.39 | -41.30 | -362.69 | -1,100.64 |
| Net Income Discontinuous Operations | 0 | -50.21 | -11.95 | -997.96 |
| Net Income Continuous Operations | 22.39 | 8.90 | -350.74 | -102.68 |
| Other Income Expense | -137 | -83.33 | -420.36 | -216.51 |
| Other Non Operating Income Expenses | -3.13 | -1.20 | -4.59 | -3.94 |
| Special Income Charges | -133.87 | -82.13 | -415.77 | -212.57 |
| Other Special Charges | 0 | -3.52 | 1.10 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 307.11 | 0 |
| Restructuring And Mergern Acquisition | 133.87 | 82.13 | 108.65 | 212.57 |
| Net Non Operating Interest Income Expense | -128.89 | -116.77 | -107.57 | -107.18 |
| Interest Expense Non Operating | 128.89 | 116.77 | 107.57 | 107.18 |
| Other Operating Expenses | -5.25 | 6.93 | 13.32 | 0 |
| Operating Revenue | 9,955.48 | 2,552.57 | 2,680.11 | 2,762.03 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Accendra Health, Inc.this co. | ACH | $267M | - | -0.58 | 238.8% | 5.96 |
| RxSight, Inc. | RXST | $282M | - | 1.02 | -14.1% | -1.42 |
| Foghorn Therapeutics Inc. | FHTX | $279M | - | -2.49 | 68.5% | -2.05 |
| Editas Medicine, Inc. | EDIT | $276M | - | 10.11 | -586.6% | -1.57 |
| Eledon Pharmaceuticals, Inc. | ELDN | $266M | - |
| 1.84 |
| -56.3% |
| - |
| TriSalus Life Sciences, Inc. | TLSI | $262M | - | -6.29 | 115.8% | -10.46 |
| Coherus Oncology, Inc. | CHRS | $261M | - | 3.45 | 275.4% | -0.83 |
| Codexis, Inc. | CDXS | $255M | - | 5.04 | -87.0% | -7.57 |
| Alector, Inc. | ALEC | $255M | - | 8.27 | -466.3% | -0.23 |
| Peer Median | - | - | 2.65 | -35.2% | -1.57 | |